{"id":109656,"date":"2021-03-16T13:03:50","date_gmt":"2021-03-16T13:03:50","guid":{"rendered":"https:\/\/fin2me.com\/?p=109656"},"modified":"2021-03-16T13:03:50","modified_gmt":"2021-03-16T13:03:50","slug":"germanys-astrazeneca-move-could-stymie-recovery-economists-say","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/","title":{"rendered":"Germany's AstraZeneca move could stymie recovery, economists say"},"content":{"rendered":"

BERLIN (Reuters) – Germany\u2019s decision to suspend AstraZeneca\u2019s COVID-19 vaccine could delay progress in reaching herd immunity and postpone a much-hoped for easing of lockdown measures needed for a robust recovery in the second quarter, economists said on Tuesday.<\/p>

FILE PHOTO: Vials labelled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed Germany flag in this illustration photo taken March 14, 2021. REUTERS\/Dado Ruvic\/Illustration<\/figcaption>

Health Minister Jens Spahn described Monday\u2019s move on the AstraZeneca shot as a precaution, making Germany the latest of several European countries to hit pause following reports of blood coagulation disorders in some recipients.<\/p>\n

The government\u2019s decision was based on a recommendation from the politically independent Paul Ehrlich Institute (PEI), Germany\u2019s authority in charge of vaccines, following newly registered cases of a very rare cerebral vein thrombosis, including three deaths.<\/p>\n

\u201cFrom an economic point of view, the problems with the AstraZeneca vaccine come at a highly unfavourable time,\u201d Commerzbank chief economist Joerg Kraemer said, pointing to an increasing number of new coronavirus infections in Germany.<\/p>\n

The crucial question now is how long use of the AstraZeneca vaccine will remain suspended, Kraemer said.<\/p>\n

EU countries that have halted AstraZeneca shots are awaiting the all-clear from the European Medicines Agency. It was due to give a news conference on Tuesday at 1300 GMT.<\/p>\n

\u201cIf it were no longer allowed to be used permanently, the point where Germany will reach herd immunity will be delayed by one to two months,\u201d Kraemer said.<\/p>

Slideshow ( 2 images )<\/span><\/figcaption>

\u2018GAME CHANGER\u2019<\/p>\n

In such a scenario, politicians would probably be forced to put the brakes on any further easing steps, which could delay the economic recovery, he added.<\/p>\n

ING chief economist Carsten Brzeski said the suspension of the AstraZeneca vaccine was increasing the risks that the economic recovery could be delayed into the third quarter.<\/p>\n

\u201cThe decision is a game changer – at least in the short term,\u201d ING chief economist Carsten Brzeski said.<\/p>\n

Brzeski said the move not only delayed what has already been a slow vaccination rollout, but also increased general vaccine scepticism among Germans as significantly fewer people might now be willing to get the AstraZeneca shot voluntarily.<\/p>\n

Germany\u2019s second lockdown has stopped a recovery in Europe\u2019s largest economy, but recent data for the first quarter suggest there won\u2019t be a \u201cdrastic plunge\u201d in gross domestic product as seen during the first lockdown, the Statistics Office said.<\/p>\n

The German economy suffered an unprecedented plunge of 9.7% in the second quarter of 2020 due to the impact of the first lockdown. It then registered record growth of 8.5% in the third quarter and continued to expand by 0.3% in the fourth quarter despite new curbs to contain a second wave of infections.<\/p>\n

A survey by ZEW economic institute conducted before the vaccine decision showed on Tuesday that investor sentiment in Germany increased by more than expected in March, buoying the outlook for a broad-based recovery.<\/p>\n

Recent German data has painted a picture of a two-speed economy, in which export-oriented manufacturers are doing well while domestically driven services are suffering under lockdown measures imposed in early November and tightened in mid-December.<\/p>\n

\u201cEconomic optimism continues to rise. Experts expect a broad-based recovery of the German economy,\u201d ZEW President Achim Wambach said in a statement.<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

BERLIN (Reuters) – Germany\u2019s decision to suspend AstraZeneca\u2019s COVID-19 vaccine could delay progress in reaching herd immunity and postpone a much-hoped for easing of lockdown […]<\/p>\n","protected":false},"author":3,"featured_media":109655,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nGermany's AstraZeneca move could stymie recovery, economists say - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Germany's AstraZeneca move could stymie recovery, economists say - Fin2me\" \/>\n<meta property=\"og:description\" content=\"BERLIN (Reuters) – Germany\u2019s decision to suspend AstraZeneca\u2019s COVID-19 vaccine could delay progress in reaching herd immunity and postpone a much-hoped for easing of lockdown [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T13:03:50+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/03\/cnewsfotor139-1.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/\",\"url\":\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/\",\"name\":\"Germany's AstraZeneca move could stymie recovery, economists say - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2021-03-16T13:03:50+00:00\",\"dateModified\":\"2021-03-16T13:03:50+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Markets\",\"item\":\"https:\/\/fin2me.com\/category\/markets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Germany's AstraZeneca move could stymie recovery, economists say\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Germany's AstraZeneca move could stymie recovery, economists say - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/","og_locale":"en_US","og_type":"article","og_title":"Germany's AstraZeneca move could stymie recovery, economists say - Fin2me","og_description":"BERLIN (Reuters) – Germany\u2019s decision to suspend AstraZeneca\u2019s COVID-19 vaccine could delay progress in reaching herd immunity and postpone a much-hoped for easing of lockdown [...]","og_url":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/","og_site_name":"Fin2me","article_published_time":"2021-03-16T13:03:50+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/03\/cnewsfotor139-1.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/","url":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/","name":"Germany's AstraZeneca move could stymie recovery, economists say - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2021-03-16T13:03:50+00:00","dateModified":"2021-03-16T13:03:50+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/markets\/germanys-astrazeneca-move-could-stymie-recovery-economists-say\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Markets","item":"https:\/\/fin2me.com\/category\/markets\/"},{"@type":"ListItem","position":3,"name":"Germany's AstraZeneca move could stymie recovery, economists say"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/109656"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=109656"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/109656\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/109655"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=109656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=109656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=109656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}